Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ovid Therapeutics Inc.

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Host Investor Event
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at Upcoming August Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers LGND OVID
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Added to Russell 3000® Index
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.